Global Quit Smoking Drug

Quit Smoking Drug Comprehensive Study by Type (Chewing Gum, Inhaler, Lozenge, Patch, Spray, Sublingual Tablets), Application (Hospital, Medical Center), Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, Online Stores), End-User (Men, Women), Treatment Type (Nicotine Replacement Therapy (NRT), Non-NRT therapy) Players and Region - Global Market Outlook to 2026

Quit Smoking Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Quit Smoking Drug Market?

Lung cancer, as well as other respiratory and heart disorders, are all linked to smoking. Individuals who are aware of these health risks are more likely to use smoking cessation counselling(Which includes quit smoking drugs). Individual awareness raised by digital media, print media, and other sources of information has proven to be effective in reducing the prevalence of nicotine addiction to some extent. Government efforts to introduce anti-smoking policies and raise awareness about the health risks associated with smoking are also expected to boost business growth. The World Health Organization (WHO) has launched the ‘Tobacco Free Initiative,' which involves clear packaging to reduce the appeal of the product and the screening of films and videos to educate the general public about the dangers of smoking. FDA-approved pharmacotherapies such as nicotine replacement therapy (NRT) in a variety of forms such as transdermal patches, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline (Chantix/Champix) are now widely accessible.

The market study is being classified by Type (Chewing Gum, Inhaler, Lozenge, Patch, Spray and Sublingual Tablets), by Application (Hospital and Medical Center) and major geographies with country level break-up.

Reckitt Benckiser Plc (United kingdom), Pfizer Inc. (United States), GlaxoSmithKline Plc (United Kimgdom), Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Johnson and Johnson (United States), Bayer AG (Germany), Cipla Ltd (India), Takeda Pharmaceuticals Co. Ltd. (Japan) and NJOY (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Quit Smoking Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Quit Smoking Drug market by Type, Application and Region.

On the basis of geography, the market of Quit Smoking Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Awareness about Health Problems Caused Because of Smoking
  • Banning Advertisements of Tobacco Products

Market Trend
  • Large Population Addicted to Smoking

Restraints
  • Lack of Awareness in Rural Areas

Opportunities
  • Government Initiatives To Encourage No Smoking

Challenges
  • Adverse Effects of These Drugs



The FDA has approved two smoking cessation products that do not contain nicotine. They are Chantix (varenicline tartrate) and Zyban (buproprion hydrochloride). Both are available in tablet form and by prescription only.

Key Target Audience
Pharmaceutical Industry, Healthcare Industry, Regulatory Bodies, Government Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Chewing Gum
  • Inhaler
  • Lozenge
  • Patch
  • Spray
  • Sublingual Tablets
By Application
  • Hospital
  • Medical Center
By Distribution Channel
  • Hospitals Pharmacies
  • Drug Stores
  • Retail Stores
  • Online Stores

By End-User
  • Men
  • Women

By Treatment Type
  • Nicotine Replacement Therapy (NRT)
  • Non-NRT therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Awareness about Health Problems Caused Because of Smoking
      • 3.2.2. Banning Advertisements of Tobacco Products
    • 3.3. Market Challenges
      • 3.3.1. Adverse Effects of These Drugs
    • 3.4. Market Trends
      • 3.4.1. Large Population Addicted to Smoking
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Quit Smoking Drug, by Type, Application, Distribution Channel, End-User, Treatment Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Quit Smoking Drug (Value)
      • 5.2.1. Global Quit Smoking Drug by: Type (Value)
        • 5.2.1.1. Chewing Gum
        • 5.2.1.2. Inhaler
        • 5.2.1.3. Lozenge
        • 5.2.1.4. Patch
        • 5.2.1.5. Spray
        • 5.2.1.6. Sublingual Tablets
      • 5.2.2. Global Quit Smoking Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Medical Center
      • 5.2.3. Global Quit Smoking Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals Pharmacies
        • 5.2.3.2. Drug Stores
        • 5.2.3.3. Retail Stores
        • 5.2.3.4. Online Stores
      • 5.2.4. Global Quit Smoking Drug by: End-User (Value)
        • 5.2.4.1. Men
        • 5.2.4.2. Women
      • 5.2.5. Global Quit Smoking Drug by: Treatment Type (Value)
        • 5.2.5.1. Nicotine Replacement Therapy (NRT)
        • 5.2.5.2. Non-NRT therapy
      • 5.2.6. Global Quit Smoking Drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Quit Smoking Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Reckitt Benckiser Plc (United kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kimgdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson and Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cipla Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceuticals Co. Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NJOY (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Quit Smoking Drug Sale, by Type, Application, Distribution Channel, End-User, Treatment Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Quit Smoking Drug (Value)
      • 7.2.1. Global Quit Smoking Drug by: Type (Value)
        • 7.2.1.1. Chewing Gum
        • 7.2.1.2. Inhaler
        • 7.2.1.3. Lozenge
        • 7.2.1.4. Patch
        • 7.2.1.5. Spray
        • 7.2.1.6. Sublingual Tablets
      • 7.2.2. Global Quit Smoking Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Medical Center
      • 7.2.3. Global Quit Smoking Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals Pharmacies
        • 7.2.3.2. Drug Stores
        • 7.2.3.3. Retail Stores
        • 7.2.3.4. Online Stores
      • 7.2.4. Global Quit Smoking Drug by: End-User (Value)
        • 7.2.4.1. Men
        • 7.2.4.2. Women
      • 7.2.5. Global Quit Smoking Drug by: Treatment Type (Value)
        • 7.2.5.1. Nicotine Replacement Therapy (NRT)
        • 7.2.5.2. Non-NRT therapy
      • 7.2.6. Global Quit Smoking Drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Quit Smoking Drug: by Type(USD Million)
  • Table 2. Quit Smoking Drug Chewing Gum , by Region USD Million (2015-2020)
  • Table 3. Quit Smoking Drug Inhaler , by Region USD Million (2015-2020)
  • Table 4. Quit Smoking Drug Lozenge , by Region USD Million (2015-2020)
  • Table 5. Quit Smoking Drug Patch , by Region USD Million (2015-2020)
  • Table 6. Quit Smoking Drug Spray , by Region USD Million (2015-2020)
  • Table 7. Quit Smoking Drug Sublingual Tablets , by Region USD Million (2015-2020)
  • Table 8. Quit Smoking Drug: by Application(USD Million)
  • Table 9. Quit Smoking Drug Hospital , by Region USD Million (2015-2020)
  • Table 10. Quit Smoking Drug Medical Center , by Region USD Million (2015-2020)
  • Table 11. Quit Smoking Drug: by Distribution Channel(USD Million)
  • Table 12. Quit Smoking Drug Hospitals Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Quit Smoking Drug Drug Stores , by Region USD Million (2015-2020)
  • Table 14. Quit Smoking Drug Retail Stores , by Region USD Million (2015-2020)
  • Table 15. Quit Smoking Drug Online Stores , by Region USD Million (2015-2020)
  • Table 16. Quit Smoking Drug: by End-User(USD Million)
  • Table 17. Quit Smoking Drug Men , by Region USD Million (2015-2020)
  • Table 18. Quit Smoking Drug Women , by Region USD Million (2015-2020)
  • Table 19. Quit Smoking Drug: by Treatment Type(USD Million)
  • Table 20. Quit Smoking Drug Nicotine Replacement Therapy (NRT) , by Region USD Million (2015-2020)
  • Table 21. Quit Smoking Drug Non-NRT therapy , by Region USD Million (2015-2020)
  • Table 22. South America Quit Smoking Drug, by Country USD Million (2015-2020)
  • Table 23. South America Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 24. South America Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 25. South America Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 26. South America Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 27. South America Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 28. Brazil Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 29. Brazil Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 30. Brazil Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 31. Brazil Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 32. Brazil Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 33. Argentina Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 34. Argentina Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 35. Argentina Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 36. Argentina Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 37. Argentina Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 38. Rest of South America Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 40. Rest of South America Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 41. Rest of South America Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 42. Rest of South America Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 43. Asia Pacific Quit Smoking Drug, by Country USD Million (2015-2020)
  • Table 44. Asia Pacific Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 45. Asia Pacific Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 46. Asia Pacific Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 47. Asia Pacific Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 48. Asia Pacific Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 49. China Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 50. China Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 51. China Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 52. China Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 53. China Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 54. Japan Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 55. Japan Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 56. Japan Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 57. Japan Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 58. Japan Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 59. India Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 60. India Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 61. India Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 62. India Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 63. India Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 64. South Korea Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 65. South Korea Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 66. South Korea Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 67. South Korea Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 68. South Korea Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 69. Taiwan Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 70. Taiwan Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 71. Taiwan Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 72. Taiwan Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 73. Taiwan Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 74. Australia Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 75. Australia Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 76. Australia Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 77. Australia Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 78. Australia Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 84. Europe Quit Smoking Drug, by Country USD Million (2015-2020)
  • Table 85. Europe Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 86. Europe Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 87. Europe Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 88. Europe Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 89. Europe Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 90. Germany Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 91. Germany Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 92. Germany Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 93. Germany Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 94. Germany Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 95. France Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 96. France Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 97. France Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 98. France Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 99. France Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 100. Italy Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 101. Italy Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 102. Italy Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 103. Italy Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 104. Italy Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 105. United Kingdom Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 106. United Kingdom Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 107. United Kingdom Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 108. United Kingdom Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 109. United Kingdom Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 110. Netherlands Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 111. Netherlands Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 112. Netherlands Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 113. Netherlands Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 114. Netherlands Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 115. Rest of Europe Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 116. Rest of Europe Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 117. Rest of Europe Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 118. Rest of Europe Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 119. Rest of Europe Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 120. MEA Quit Smoking Drug, by Country USD Million (2015-2020)
  • Table 121. MEA Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 122. MEA Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 123. MEA Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 124. MEA Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 125. MEA Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 126. Middle East Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 127. Middle East Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 128. Middle East Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 129. Middle East Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 130. Middle East Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 131. Africa Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 132. Africa Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 133. Africa Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 134. Africa Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 135. Africa Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 136. North America Quit Smoking Drug, by Country USD Million (2015-2020)
  • Table 137. North America Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 138. North America Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 139. North America Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 140. North America Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 141. North America Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 142. United States Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 143. United States Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 144. United States Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 145. United States Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 146. United States Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 147. Canada Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 148. Canada Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 149. Canada Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 150. Canada Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 151. Canada Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 152. Mexico Quit Smoking Drug, by Type USD Million (2015-2020)
  • Table 153. Mexico Quit Smoking Drug, by Application USD Million (2015-2020)
  • Table 154. Mexico Quit Smoking Drug, by Distribution Channel USD Million (2015-2020)
  • Table 155. Mexico Quit Smoking Drug, by End-User USD Million (2015-2020)
  • Table 156. Mexico Quit Smoking Drug, by Treatment Type USD Million (2015-2020)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Quit Smoking Drug: by Type(USD Million)
  • Table 168. Quit Smoking Drug Chewing Gum , by Region USD Million (2021-2026)
  • Table 169. Quit Smoking Drug Inhaler , by Region USD Million (2021-2026)
  • Table 170. Quit Smoking Drug Lozenge , by Region USD Million (2021-2026)
  • Table 171. Quit Smoking Drug Patch , by Region USD Million (2021-2026)
  • Table 172. Quit Smoking Drug Spray , by Region USD Million (2021-2026)
  • Table 173. Quit Smoking Drug Sublingual Tablets , by Region USD Million (2021-2026)
  • Table 174. Quit Smoking Drug: by Application(USD Million)
  • Table 175. Quit Smoking Drug Hospital , by Region USD Million (2021-2026)
  • Table 176. Quit Smoking Drug Medical Center , by Region USD Million (2021-2026)
  • Table 177. Quit Smoking Drug: by Distribution Channel(USD Million)
  • Table 178. Quit Smoking Drug Hospitals Pharmacies , by Region USD Million (2021-2026)
  • Table 179. Quit Smoking Drug Drug Stores , by Region USD Million (2021-2026)
  • Table 180. Quit Smoking Drug Retail Stores , by Region USD Million (2021-2026)
  • Table 181. Quit Smoking Drug Online Stores , by Region USD Million (2021-2026)
  • Table 182. Quit Smoking Drug: by End-User(USD Million)
  • Table 183. Quit Smoking Drug Men , by Region USD Million (2021-2026)
  • Table 184. Quit Smoking Drug Women , by Region USD Million (2021-2026)
  • Table 185. Quit Smoking Drug: by Treatment Type(USD Million)
  • Table 186. Quit Smoking Drug Nicotine Replacement Therapy (NRT) , by Region USD Million (2021-2026)
  • Table 187. Quit Smoking Drug Non-NRT therapy , by Region USD Million (2021-2026)
  • Table 188. South America Quit Smoking Drug, by Country USD Million (2021-2026)
  • Table 189. South America Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 190. South America Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 191. South America Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 192. South America Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 193. South America Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 194. Brazil Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 195. Brazil Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 196. Brazil Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 197. Brazil Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 198. Brazil Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 199. Argentina Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 200. Argentina Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 201. Argentina Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 202. Argentina Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 203. Argentina Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 204. Rest of South America Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 205. Rest of South America Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 206. Rest of South America Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 207. Rest of South America Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 208. Rest of South America Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 209. Asia Pacific Quit Smoking Drug, by Country USD Million (2021-2026)
  • Table 210. Asia Pacific Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 211. Asia Pacific Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 212. Asia Pacific Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 213. Asia Pacific Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 214. Asia Pacific Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 215. China Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 216. China Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 217. China Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 218. China Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 219. China Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 220. Japan Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 221. Japan Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 222. Japan Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 223. Japan Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 224. Japan Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 225. India Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 226. India Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 227. India Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 228. India Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 229. India Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 230. South Korea Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 231. South Korea Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 232. South Korea Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 233. South Korea Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 234. South Korea Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 235. Taiwan Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 236. Taiwan Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 237. Taiwan Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 238. Taiwan Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 239. Taiwan Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 240. Australia Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 241. Australia Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 242. Australia Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 243. Australia Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 244. Australia Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 250. Europe Quit Smoking Drug, by Country USD Million (2021-2026)
  • Table 251. Europe Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 252. Europe Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 253. Europe Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 254. Europe Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 255. Europe Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 256. Germany Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 257. Germany Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 258. Germany Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 259. Germany Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 260. Germany Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 261. France Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 262. France Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 263. France Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 264. France Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 265. France Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 266. Italy Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 267. Italy Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 268. Italy Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 269. Italy Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 270. Italy Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 271. United Kingdom Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 272. United Kingdom Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 273. United Kingdom Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 274. United Kingdom Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 275. United Kingdom Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 276. Netherlands Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 277. Netherlands Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 278. Netherlands Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 279. Netherlands Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 280. Netherlands Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 281. Rest of Europe Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 282. Rest of Europe Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 283. Rest of Europe Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 284. Rest of Europe Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 285. Rest of Europe Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 286. MEA Quit Smoking Drug, by Country USD Million (2021-2026)
  • Table 287. MEA Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 288. MEA Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 289. MEA Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 290. MEA Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 291. MEA Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 292. Middle East Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 293. Middle East Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 294. Middle East Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 295. Middle East Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 296. Middle East Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 297. Africa Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 298. Africa Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 299. Africa Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 300. Africa Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 301. Africa Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 302. North America Quit Smoking Drug, by Country USD Million (2021-2026)
  • Table 303. North America Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 304. North America Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 305. North America Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 306. North America Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 307. North America Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 308. United States Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 309. United States Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 310. United States Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 311. United States Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 312. United States Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 313. Canada Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 314. Canada Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 315. Canada Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 316. Canada Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 317. Canada Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 318. Mexico Quit Smoking Drug, by Type USD Million (2021-2026)
  • Table 319. Mexico Quit Smoking Drug, by Application USD Million (2021-2026)
  • Table 320. Mexico Quit Smoking Drug, by Distribution Channel USD Million (2021-2026)
  • Table 321. Mexico Quit Smoking Drug, by End-User USD Million (2021-2026)
  • Table 322. Mexico Quit Smoking Drug, by Treatment Type USD Million (2021-2026)
  • Table 323. Research Programs/Design for This Report
  • Table 324. Key Data Information from Secondary Sources
  • Table 325. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Quit Smoking Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Quit Smoking Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Quit Smoking Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Quit Smoking Drug: by End-User USD Million (2015-2020)
  • Figure 8. Global Quit Smoking Drug: by Treatment Type USD Million (2015-2020)
  • Figure 9. South America Quit Smoking Drug Share (%), by Country
  • Figure 10. Asia Pacific Quit Smoking Drug Share (%), by Country
  • Figure 11. Europe Quit Smoking Drug Share (%), by Country
  • Figure 12. MEA Quit Smoking Drug Share (%), by Country
  • Figure 13. North America Quit Smoking Drug Share (%), by Country
  • Figure 14. Global Quit Smoking Drug share by Players 2020 (%)
  • Figure 15. Global Quit Smoking Drug share by Players (Top 3) 2020(%)
  • Figure 16. Global Quit Smoking Drug share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Reckitt Benckiser Plc (United kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Reckitt Benckiser Plc (United kingdom) Revenue: by Geography 2020
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 22. GlaxoSmithKline Plc (United Kimgdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Plc (United Kimgdom) Revenue: by Geography 2020
  • Figure 24. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 30. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 32. Cipla Ltd (India) Revenue, Net Income and Gross profit
  • Figure 33. Cipla Ltd (India) Revenue: by Geography 2020
  • Figure 34. Takeda Pharmaceuticals Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takeda Pharmaceuticals Co. Ltd. (Japan) Revenue: by Geography 2020
  • Figure 36. NJOY (United States) Revenue, Net Income and Gross profit
  • Figure 37. NJOY (United States) Revenue: by Geography 2020
  • Figure 38. Global Quit Smoking Drug: by Type USD Million (2021-2026)
  • Figure 39. Global Quit Smoking Drug: by Application USD Million (2021-2026)
  • Figure 40. Global Quit Smoking Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 41. Global Quit Smoking Drug: by End-User USD Million (2021-2026)
  • Figure 42. Global Quit Smoking Drug: by Treatment Type USD Million (2021-2026)
  • Figure 43. South America Quit Smoking Drug Share (%), by Country
  • Figure 44. Asia Pacific Quit Smoking Drug Share (%), by Country
  • Figure 45. Europe Quit Smoking Drug Share (%), by Country
  • Figure 46. MEA Quit Smoking Drug Share (%), by Country
  • Figure 47. North America Quit Smoking Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Reckitt Benckiser Plc (United kingdom)
  • Pfizer Inc. (United States)
  • GlaxoSmithKline Plc (United Kimgdom)
  • Hoffmann-La Roche AG (Switzerland)
  • Novartis AG (Switzerland)
  • Johnson and Johnson (United States)
  • Bayer AG (Germany)
  • Cipla Ltd (India)
  • Takeda Pharmaceuticals Co. Ltd. (Japan)
  • NJOY (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 237 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Quit Smoking Drug Quantitative research analysis
Global Quit Smoking Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Awareness about Health Problems Caused Because of Smoking " is seen as one of major growth factors of Quit Smoking Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Quit Smoking Drug Report?

Have a Query? Click Here

Other Related Reports

Anti-Neprilysin Comprehensive Study by Type (TD-0714, STR-324, PL-265, LHW-090, Others), Application (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer's Disease, Others), Distribution Channe...
$ 3650
Cholesterol Lowering Agents Comprehensive Study by Type (Statins and Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, Others), Application (Hospital...
$ 3750
Acyclovir Injection Comprehensive Study by Type (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others), Application (HIV, Hepatitis, Herpes Simplex Virus, I...
$ 3750
Liposome Assisted Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others), Application (Fungal Infection Therapy, Cancer and Tumor Th...
$ 3750
Heart Disease Drugs Comprehensive Study by Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), Disease (Hypertension, Hyperlipidemia, Coronary Artery Disease...
$ 3650
Cholesterol Drug Comprehensive Study by Type (Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin, Pitavastatin (Livalo), Pravastatin (Pravachol), Rosuvastatin calcium (Crestor), Simvastatin (Zo...
$ 3750